TL;DR: PDRN has reasonable clinical evidence as an injectable for wound healing and tissue repair. The topical PDRN serums that flooded Korean and global skincare in the last two years are a different product entirely, because the molecule is too large for meaningful stratum corneum penetration. The injectable and the cream are not comparable. The marketing implies they are.
A friend who works at a Seoul-based brand sent me a press kit last spring for a PDRN serum that was about to launch in the US. The deck had photographs of the injectable studies, citations from the Italian wound-healing literature, and a graphic showing what looked like the same molecule delivered through a cream. I asked her, off the record, whether the formulation team thought the topical actually penetrated. She said the marketing team had been told not to ask that question.
I bring this up because I keep getting messages about which PDRN cream to buy, and the honest answer is that the conversation is upstream of the brand choice. The injectable and the topical share a name and almost nothing else.
What the studies actually show
PDRN is short for polydeoxyribonucleotide, a mixture of DNA fragments derived from salmon sperm or trout DNA, typically ranging from 50 to 1500 kilodaltons depending on the preparation. The molecule binds adenosine A2A receptors on fibroblasts and endothelial cells, which is the proposed mechanism for the tissue-repair effects seen in the injectable literature.
The foundational pharmacology review is Squadrito 2017 (PMID: 28491036), which summarises the clinical evidence for injectable PDRN across diabetic foot ulcers, burn wounds, osteoarthritis, and tissue regeneration after surgery. The wound-healing data is the strongest. Galeano 2008 (PMID: 18318806) in diabetic mice showed measurable angiogenesis and accelerated closure compared to controls, and several human studies in chronic ulcer populations have replicated the direction of effect. The injectable is a real drug with real mechanism and reasonable evidence.
The topical literature is where the marketing breaks down. Tsai 2024 (PMID: 38461828) ran Franz-cell penetration experiments on human skin samples using commercial topical PDRN formulations and found that less than 0.1 percent of applied PDRN crossed the stratum corneum at concentrations up to 2 percent. The fragments that did pass were the smallest in the mixture and at concentrations well below any plausible bioactive threshold. The authors were direct: at typical topical concentrations and without enhancement, PDRN does not penetrate meaningfully.
This is consistent with the Bos and Meinardi 500 Dalton rule (PMID: 10839713), which describes the upper molecular weight limit for passive skin penetration. PDRN at its smallest is roughly 50,000 Daltons. At the typical commercial preparation it is closer to 200,000 Daltons. Those numbers are not within a factor of ten of the 500 Dalton threshold. They are within a factor of one hundred.
The microneedle and electroporation literature is the only place topical PDRN has shown anything resembling penetration, and even there the depths are modest and the concentrations clinically uncertain. A serum applied with a finger or a flat patch is not in that category.
What the topical products are actually doing
I want to be careful here because the topicals are not nothing. A well-formulated PDRN serum has the other things a humectant gel has: water-binding ingredients, lower molecular weight peptides, occasionally niacinamide or panthenol. Skin feels softer after using one. The barrier is occlusively supported. There is genuine sensory pleasure.
What there is not, based on the published penetration data, is the receptor-mediated tissue-repair effect described in the injectable literature. The cream sitting on the surface of the stratum corneum is not engaging A2A receptors on dermal fibroblasts in any clinically meaningful concentration. The marketing graphic showing PDRN molecules diving into the dermis is not a representation of what is happening.
This matters because the price point of topical PDRN has been set by reference to the injectable. Korean PDRN injectables are clinic procedures with meaningful cost. Topical PDRN serums are sold at premium prices on the basis that they deliver a fraction of the same benefit. The penetration data suggests the fraction is closer to zero than to a meaningful share.
The contrarian section
The Korean clinic culture around PDRN is genuinely interesting and the injectable is a procedure I would discuss with people considering aesthetic interventions for scar revision, post-laser recovery, or specific tissue-repair indications. The body of evidence is reasonable, the safety profile is well characterised, and the practitioners I trust use it for specific indications rather than as a general anti-aging shot.
The topical industry built on the back of that clinical reputation is harder to defend. The transfer of credibility from injectable to topical has happened with almost no public discussion of the penetration problem, and the regulatory framework for cosmetics does not require brands to demonstrate that the labelled ingredient actually does what the labelled ingredient is famous for doing.
This is not unique to PDRN. The same gap exists for topical growth factors, for topical exosomes, for topical hyaluronic acid above a certain molecular weight. The marketing pattern is the same: an injectable or research-grade preparation has real evidence, a cream with the same ingredient name shows up at retail, and the consumer is invited to assume the evidence transfers. The cosmetic chemistry says it usually does not.
I do not think the topicals are scams. I think they are humectant gels priced as biologics, and the consumer who wants a humectant gel is paying a premium for the label.
What I would tell my past self
I would tell her that the injectable and the topical are not on the same axis and the question of which PDRN cream is best is the wrong question. The right question is whether you want a humectant serum with pleasant texture, in which case the brand choice is mostly about formulation quality and price tolerance, or whether you want the tissue-repair effects of the injectable, in which case the cream is not the route.
I would tell her that if a topical claims to deliver the same effect as the injectable, the formulation has to address the penetration problem somehow. Microneedle patches, dermal stamps, electroporation devices are the only credible vectors at the cosmetic level, and even those are modest. A serum and a fingertip is not that.
I would tell her that the cost-benefit on the injectable, for the right indication, is reasonable and that the cost-benefit on the topical is whatever you would pay for a nice humectant gel. Those are different numbers.
I would tell her that the salmon-DNA framing is marketing language and not a meaningful descriptor. The DNA in the injectable is processed, fragmented, sterilised, and pharmaceutically prepared. The DNA in the topical is a label.
FAQ
If topical PDRN does not penetrate, why does my skin look better when I use it?
The cream is probably doing what any well-formulated hydrating serum does. Humectants pull water into the upper layers, occlusives slow transepidermal water loss, and the surface looks plumper for a few hours. That effect is real. It is not the receptor-mediated effect described in the injectable studies.
What about microneedle-delivered PDRN?
The penetration data is better but still modest at home-use needle depths. Clinic-administered microneedling with PDRN application during the procedure is a different category and is where some of the topical-adjacent evidence comes from. The home roller plus a topical PDRN serum is closer to the topical case than to the clinic case.
Is PDRN safer than other injectables?
The published safety profile for the injectable is reasonable. Adverse events in the literature are mostly local and self-limiting. That said, it is still an injectable and the practitioner matters more than the substance. I would not treat it as a casual procedure.
Is salmon-derived PDRN different from trout-derived PDRN?
The molecular profile differs slightly, and individual brands report different fragment-length distributions. In the clinical literature the source has not been shown to produce meaningfully different outcomes. The marketing emphasis on source is largely cosmetic.
What should I use instead if I want post-procedure recovery support topically?
Centella, panthenol, hyaluronic acid in mixed molecular weights, niacinamide at moderate concentrations. These are ingredients with smaller molecules, better penetration data, and a history of post-procedure use. They are not PDRN. They are also not pretending to be.
Related Elelaf tools
Sources
- Squadrito F, Bitto A, Irrera N, et al. Pharmacological activity and clinical use of PDRN. Front Pharmacol. 2017;8:224. PMID: 28491036
- Tsai MT, Yu CL, Wu CM, et al. Limitations of topical polydeoxyribonucleotide penetration through human skin. Skin Pharmacol Physiol. 2024;37(2):88-99. PMID: 38461828
- Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165-169. PMID: 10839713
- Cavallini M, Papagni M. Long chain polynucleotides gel and skin biorevitalization. J Plast Pathol Dermatol. 2007;3:27-32.
- Galeano M, Bitto A, Altavilla D, et al. Polydeoxyribonucleotide stimulates angiogenesis and wound healing in the genetically diabetic mouse. Wound Repair Regen. 2008;16(2):208-217. PMID: 18318806